Extended Data Fig. 2: Pharmacodynamic analysis of study agents.
From: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
a–d, Quantification of western blots for phospho-S6 (a,b) or LC3-II (c,d) performed on lysates of proliferative (a,c) or dormant (b,d) Her2-inducible primary tumor cells in vitro treated with vehicle (VEH), rapamycin (RAPA), everolimus (EVE), hydroxychloroquine [HCQ] or EVE + HCQ. A recurrent Her2 tumor cell line is shown as a control for proliferative samples. Proliferative and dormant VEH controls are shown for scale to the right. Representative western blots for proliferative (e) and dormant (f) tumor cells corresponding to a–d. g–j, Quantification of western blots for phospho-S6 (a,b) or LC3-II (c,d) performed on lysates of primary orthotopic tumors (g,i) or dormant residual orthotopic tumors (h,j) derived from Her2-inducible primary tumor cells collected from mice treated with VEH, RAPA, EVE, CQ, HCQ or EVE + HCQ. Primary tumor and dormant tumor VEH controls are shown for scale to the right. Representative western blots for primary tumor (k) and dormant (l) tumor lysates corresponding to g–j. Bars and error bars show mean ± s.e.m. Molecular weight markers are shown. For l, a dotted vertical line indicates where the molecular weight marker lanes were not immediately adjacent to the samples shown (which were otherwise contiguous).
